World's Best Scientists 2026 revealed!
Evelyna Derhovanessian

Evelyna Derhovanessian

D-Index & Metrics

Immunology

D-Index
44
Citations
19257
World Ranking
4736
National Ranking
308

Evelyna Derhovanessian publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Evelyna Derhovanessian sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 99 publications — 3rd percentile

3% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Evelyna Derhovanessian D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Evelyna Derhovanessian sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 44 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Evelyna Derhovanessian is affiliated with BioNTech in Germany and has contributed extensively to research in medicine, with a particular focus on immunology and oncology. The scientist's work spans several subfields, including oncology, immunology, infectious diseases, molecular biology, and radiology.

Their research centers on main topics such as immunotherapy and immune responses, cancer immunotherapy and biomarkers, CAR-T cell therapy research, SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, RNA interference and gene delivery, and monoclonal and polyclonal antibodies research.

Recent publications authored or co-authored by Evelyna Derhovanessian include the following:

  • COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, 2020, Nature
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer, 2023, Nature
  • An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma, 2020, Nature
  • BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans, 2021, Nature
  • BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans, 2020, bioRxiv (Cold Spring Harbor Laboratory)

Evelyna Derhovanessian has collaborated frequently with several co-authors, including:

  • Uğur Şahin
  • Özlem Türeci
  • Isabel Vogler
  • Daniel Maurus
  • Julian Sikorski

Publication venues where their research has appeared most frequently include:

  • Nature
  • Regular and Young Investigator Award Abstracts
  • Annals of Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research

The primary fields of study involved in the scientist's work are medicine and immunology and microbiology, with 34 and 15 publications respectively. The significant overlap between oncology and immunology in their subfield research highlights a focus on cancer-related immune mechanisms and therapeutic approaches.

Best Publications

  • Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

    Ugur Sahin;Evelyna Derhovanessian;Matthias Miller;Björn-Philipp Kloke

  • COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

    Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  • Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

    Lena M. Kranz;Mustafa Diken;Heinrich Haas;Sebastian Kreiter

  • Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

    Steffen Walter;Toni Weinschenk;Arnulf Stenzl;Romuald Zdrojowy

  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

    Unknown

  • An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

    Ugur Sahin;Petra Oehm;Evelyna Derhovanessian;Robert A. Jabulowsky

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

    Ugur Sahin;Alexander Muik;Isabel Vogler;Evelyna Derhovanessian

  • Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.

    Benjamin Weide;Steve Pascolo;Birgit Scheel;Evelyna Derhovanessian

  • Inflammation, ageing and chronic disease

    Graham Pawelec;David Goldeck;Evelyna Derhovanessian

  • Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

    Sven Koch;Sven Koch;Anis Larbi;Evelyna Derhovanessian;Dennis Özcelik

  • Cytomegalovirus and human immunosenescence.

    Graham Pawelec;Evelyna Derhovanessian;Anis Larbi;Jan Strindhall

  • Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

    Benjamin Weide;Alexander Martens;Henning Zelba;Christina Stutz

  • Role of CMV in immune senescence.

    Graham Pawelec;Evelyna Derhovanessian

  • Biomarkers of human immunosenescence: impact of Cytomegalovirus infection.

    Evelyna Derhovanessian;Anis Larbi;Graham Pawelec

  • Senescence of the Human Immune System

    G. Pawelec;A. Larbi;E. Derhovanessian

  • Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease.

    Anis Larbi;Graham Pawelec;Jacek M. Witkowski;Hyman M. Schipper

  • Immunosenescence and cancer.

    Graham Pawelec;Evelyna Derhovanessian;Anis Larbi

  • Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans.

    Evelyna Derhovanessian;Andrea B. Maier;Karin H. Hähnel;Robert Beck

  • Immunity, ageing and cancer

    Evelyna Derhovanessian;Rafael Solana;Anis Larbi;Graham Pawelec

  • CMV and Immunosenescence: from basics to clinics

    Rafael Solana;Raquel Tarazona;Allison E Aiello;Arne N Akbar

Frequent Co-Authors

Ugur Sahin
Ugur Sahin Johannes Gutenberg University of Mainz
David Capper
David Capper Charité - University Medicine Berlin
Özlem Türeci
Özlem Türeci BioNTech (Germany)
Hans-Georg Rammensee
Hans-Georg Rammensee University of Tübingen
Stefan Stevanovic
Stefan Stevanovic University of Tübingen
Per thor Straten
Per thor Straten University of Copenhagen
Andreas von Deimling
Andreas von Deimling Heidelberg University
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Philip R. Dormitzer
Philip R. Dormitzer Pfizer (United States)
Pei-Yong Shi
Pei-Yong Shi GlaxoSmithKline (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career opportunities. Many professionals consider accelerated routes to quickly enter the field. For example, an nurse practitioner accelerated program allows registered nurses to advance their qualifications and expand their clinical roles efficiently.

Individuals without prior nursing experience can explore flexible options like online BSN programs for non nurses, which provide foundational nursing education through virtual platforms. These programs cater to career changers and busy professionals seeking to enter the healthcare workforce.

If speed and accessibility are priorities, many students find 12-month accelerated nursing programs appealing. These intense courses are designed to prepare students for licensing exams and clinical practice in a condensed timeframe, ideal for those eager to start their healthcare careers swiftly.

For entry-level nursing roles, exploring accredited LPN programs easy to get into can be a practical step. Licensed Practical Nurse programs provide foundational skills and allow graduates to work under registered nurses or physicians, making it a solid pathway into the healthcare system related to Immunology.

Best Scientists Citing Evelyna Derhovanessian

Trending Scientists

Recently Published Articles